As a leading company in radiopharmaceutical targeted diagnosis and treatment, Sinotau Pharmaceutical announced a Series D financing of RMB 320 million. This follows the RMB 280 million raised in Series C financing in July 2020 from investors such as Ruiyi Innovation Investment Fund and Sinopharm Capital. With this recent financing, the company has raised a total of RMB 600 million within six months. The Series D funding was led by CICC Capital, with participation from Everest Venture Capital, Longmen Venture Capital, Panya Investment, and Deyi Capital, as well as existing investor Lotus Lake Capital. The raised funds will continue to be used for pre-clinical development and clinical research of therapeutic and diagnostic radiopharmaceutical projects.

CEC Capital Group served as the exclusive financial advisor for Sinotau Pharmaceutical in this transaction.

Sinotau Pharmaceutical is an innovative pharmaceutical company specialized in the research, production, and clinical promotion of radiopharmaceuticals. Leveraging leading research and development resources in radiopharmaceuticals and monoclonal antibodies worldwide, the company has established a portfolio of targeted therapeutic and precision diagnostic radiopharmaceuticals in the fields of oncology, neurodegenerative diseases, and cardiovascular diseases. Through a combination of in-house development and external collaborations, the company has built a product pipeline that balances “therapeutically equivalent” and innovation while managing risk and return. Currently, four diagnostic drugs and two therapeutic drugs from the company's pipeline have entered the clinical trial stage.